18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ Patients must meet ALL criteria listed below for entry:
• Biochemically diagnosed ACTH-dependent Cushing disease.
• No previous pituitary surgery.
• Planned to undergo pituitary surgery for localization/resection of adenoma.
• No contraindications for PET/CT.
• Recent (within 3 months) pituitary MR, or pending pituitary MR to be performed as close as possible to FET PET/CT.
• Age ≥ 18 years.
• Ability to provide informed consent.
Locations
United States
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Brent Gessner, MBA
Gessner.Brent@mayo.edu
507-284-2950
Time Frame
Start Date: 2026-04
Estimated Completion Date: 2028-07
Participants
Target number of participants: 50
Treatments
Experimental: (ACTH)-dependent Cushing disease
Patients with adrenocorticotropic hormone (ACTH)-dependent Cushing disease who may be considered candidates for surgical treatment
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic